Moderna Therapeutics watched its share price slip within hours of pulling off the biggest initial public offering in biotech history, a sign the company and its underwriters might have over-estimated demand for the richly valued company.
Moderna, headquartered in Cambridge, Mass., priced its offering at $23 per share Thursday but opened trading down about 4 percent Friday, leaving IPO buyers instantly underwater.
By the time the markets closed, shared were down 19 percent.
Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!
A-Z of Stock Markets: Underwriters
Log In | Learn More
What is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.